Top

Published in:

Open Access 01-12-2024 | Benzodiazepine | Research

Prevalence, country-specific prescribing patterns and determinants of benzodiazepine use in community-residing older adults in 7 European countries

Authors: Anna Lukačišinová, Jindra Reissigová, Maja Ortner-Hadžiabdić, Jovana Brkic, Betul Okuyan, Daisy Volmer, Ivana Tadić, Pilar Modamio, Eduardo L. Mariño, Konstantine Tachkov, Rosa Liperotti, Graziano Onder, Harriet Finne-Soveri, Hein van Hout, Elizabeth P. Howard, Daniela Fialová

Published in: BMC Geriatrics | Issue 1/2024

Abstract

Background

The use of benzodiazepines (BZDs) in older population is often accompanied by drug-related complications. Inappropriate BZD use significantly alters older adults’ clinical and functional status. This study compares the prevalence, prescribing patterns and factors associated with BZD use in community-dwelling older patients in 7 European countries.

Methods

International, cross-sectional study was conducted in community-dwelling older adults (65 +) in the Czech Republic, Serbia, Estonia, Bulgaria, Croatia, Turkey, and Spain between Feb2019 and Mar2020. Structured and standardized questionnaire based on interRAI assessment scales was applied. Logistic regression was used to evaluate factors associated with BZD use.

Results

Out of 2,865 older patients (mean age 73.2 years ± 6.8, 61.2% women) 14.9% were BZD users. The highest prevalence of BZD use was identified in Croatia (35.5%), Spain (33.5%) and Serbia (31.3%). The most frequently prescribed BZDs were diazepam (27.9% of 426 BZD users), alprazolam (23.7%), bromazepam (22.8%) and lorazepam (16.7%). Independent factors associated with BZD use were female gender (OR 1.58, 95%CI 1.19–2.10), hyperpolypharmacy (OR 1.97, 95%CI 1.22–3.16), anxiety (OR 4.26, 95%CI 2.86–6.38), sleeping problems (OR 4.47, 95%CI 3.38–5.92), depression (OR 1.95, 95%CI 1.29–2.95), repetitive anxious complaints (OR 1.77, 95%CI 1.29–2.42), problems with syncope (OR 1.78, 95%CI 1.03–3.06), and loss of appetite (OR 0.60, 95%CI 0.38–0.94). In comparison to Croatia, residing in other countries was associated with lower odds of BZD use (ORs varied from 0.49 (95%CI 0.32–0.75) in Spain to 0.01 (95%CI 0.00–0.03) in Turkey), excluding Serbia (OR 1.11, 95%CI 0.79–1.56).

Conclusions

Despite well-known negative effects, BZDs are still frequently prescribed in older outpatient population in European countries. Principles of safer geriatric prescribing and effective deprescribing strategies should be individually applied in older BZD users.

Available only for authorised users

McIntosh B, Clark M, Spry C. Benzodiazepines in older adults: A review of clinical effectiveness, cost-effectiveness, and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2011 (Rapid Response Report: Peer-Reviewed Summary with Critical Appraisal). https://www.ncbi.nlm.nih.gov/books/NBK174561/pdf/Bookshelf_NBK174561.pdf. Accessed 22 Dec 2022.

Danish Health and Medicines Authority. Effective effort against the excessive use of benzodiazepines in Denmark. http://www.dkma.dk/en/topics/statistics-prices-and-reimbursement/statistics-and-analyses/analyses/consumptionanalyses/effective-effort-against-the-excessive-u--in-denmark. Accessed 22 Dec 2022.

Medicines and Healthcare products Regulatory Agency (MHRA). Addiction to benzodiazepines and codeine: supporting safer use. July 2011. http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON123123. Accessed 22 Dec 2022.

Haute Autorité de Santé. Modalités d’arrêt des benzodiazépines et médicaments apparentés chez le patient âgé. 2007. http://www.has-sante.fr/portail/jcms/c_601509/modalites-d-arret-des-benzodiazepines-et-medicaments-apparentes-chez-le-patient-age?xtmc=benzodiaz%E9pines&xtcr=4. Accessed 22 Dec 2022.

Bachhuber MA, Hennessy S, Cunningham CO, et al. Increasing benzodiazepine prescriptions and overdose mortality in the United States, 1996–2013. Am J Public Health. 2016;106:686–8. https://doi.org/10.2105/AJPH.2016.303061.CrossRefPubMedCentralPubMed

Organisation for Economic Co-operation and Development. OECD/EU database. https://stats.oecd.org/index.aspx?DataSetCode=HEALTH_STAT. Accessed: 11 Dec 2023.

Lyons JS, Larson DB, Hromco J. Clinical and economic evaluation of benzodiazepines: a value analysis. Pharmacoeconomics. 1992;2:397–407.CrossRefPubMed

Simon GE, Ludman EJ. Outcome of new benzodiazepine prescriptions to older adults in primary care. Gen Hosp Psychiatry. 2006;28(5):374–8. https://doi.org/10.1016/j.genhosppsych.2006.05.008.CrossRefPubMedCentralPubMed

Maust DT, Kales HC, Wiechers IR, et al. No end in sight: benzodiazepine use in older adults in the United States. J Am Geriatr Soc. 2016;64(12):2546–53. https://doi.org/10.1111/jgs.14379.CrossRefPubMedCentralPubMed

10.

Rothberg MB, Herzig SJ, Pekow PS, Avrunin J, Lagu T, Lindenauer PK. Association between sedating medications and delirium in older inpatients. J Am Geriatr Soc. 2013;61(6):923–30. https://doi.org/10.1111/jgs.12253.CrossRefPubMed

11.

Gallacher J, Elwood P, Pickering J, et al. Benzodiazepine use and risk of dementia: evidence from the Caerphilly prospective study (CaPS). J Epidemiol Commun Health. 2012;66(10):869–73. https://doi.org/10.1136/jech-2011-200314.CrossRef

12.

Woolcott JC, Richardson KJ, Wiens MO, et al. Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med. 2009;169(21):1952–60. https://doi.org/10.1001/archinternmed.2009.357.CrossRefPubMed

13.

Koechl B, Unger A, Fischer G. Age-related aspects of addiction. Gerontology. 2012;58(6):540–4. https://doi.org/10.1159/000339095.CrossRefPubMed

14.

Ashton H. The diagnosis and management of benzodiazepine dependence. Curr Opin Psychiatry. 2005;18(3):249–55.CrossRefPubMed

15.

Dionne PA, Vasiliadis EM, Latimer E, et al. Economic impact of inappropriate benzodiazepine prescribing and related drug interactions among elderly persons. Psychiatr Serv. 2013;64:331–8. https://doi.org/10.1176/appi.ps.201200089.CrossRefPubMed

16.

Burrows AB, Morris JN, Simon SE, et al. Development of a minimum data set-based depression rating scale for use in nursing homes. Age Ageing. 2000;29(2):165–72. https://doi.org/10.1093/ageing/29.2.165.CrossRefPubMed

17.

World Health Organisation Collaborating Centre for Drug Statistics Methodology. The Anatomical Therapeutic Chemical (ATC) classification system and the Defined Daily Dose (DDD). https://www.whocc.no/ Updated March 23, 2020.Accessed 22 Dec 2022.

18.

Renom-Guiteras A, Meyer G, Thürmann PA. The EU(7)-PIMlist: a list of potentially inappropriate medications for older people consented by experts from seven European countries. Eur J Clin Pharmacol. 2015;71:861–75. https://doi.org/10.1007/s00228-015-1860-9.CrossRefPubMedCentralPubMed

19.

By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2019;67(4):674–94. https://doi.org/10.1111/jgs.15767.CrossRef

20.

O’Mahony D, O’Sullivan D, Byrne S, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44:213–8. https://doi.org/10.1093/ageing/afu145.CrossRefPubMed

21.

Delaš Aždajić M, Likić R, Aždajić S, et al. Outpatient benzodiazepine utilization in Croatia: drug use or misuse. Int J Clin Pharm. 2019;41:1526–35. https://doi.org/10.1007/s11096-019-00915-2.CrossRefPubMed

22.

The Agency for Medicinal Products and Medical Devices (Croatia). Medicinal Product Utilisation in Croatia (report) 2021. https://www.halmed.hr/en/Promet-proizvodnja-i-inspekcija/Promet/Potrosnja-lijekova/Izvjesca-o-prometu-lijekova/. Accessed 22 Dec 2022.

23.

Bužančić I, Pejaković TI, Ortner HM. A need for benzodiazepine deprescribing in the COVID-19 pandemic: a cohort study. Pharmacy. 2022;10(5):120. https://doi.org/10.3390/pharmacy10050120.CrossRefPubMedCentralPubMed

24.

Jakovljević M, Lacković Z. Benzodiazepini u suvremenoj medicini. 1st ed. Zagreb: Medicinska naklada; 2001.

25.

Divac N, Todorović Z, Stojanović R, et al. Utilization of psychiatric drugs in Serbia. Vojnosanit Pregl. 2009;66(3):233–7. https://doi.org/10.2298/vsp0903233d.CrossRefPubMed

26.

Divac N, Gašić J, Djukić LJ, Vujnović M, Babić D, Bajčetić M, et al. Benzodiazepines utilization and self-medication as correlates of stress in the population of Serbia. Pharmacoepidemiol Drug Saf. 2004;13(5):315–22. https://doi.org/10.1002/pds.940.CrossRefPubMed

27.

Marković SZ, Dimitrijević Jovanović NI, Sedić B, et al. Impact of differences in economic development and socioeconomic stability on benzodiazepine exposure between the three Balkans countries. Psychiatr Danub. 2019;31(Suppl 5):750–60.PubMed

28.

Perković Vukčević N, Vuković Ercegović G, Šegrt Z, et al. Benzodiazepine poisoning in elderly. Vojnosanit Pregl. 2016;73(3):234–8. https://doi.org/10.2298/VSP141208025P.CrossRef

29.

Spanish Agency for Medicines and Health Products. Circular 3/2000: Information that must appear in the data sheet of pharmaceutical specialties whose composition includes a benzodiazepine or analog (zolpidem, zopiclone), with the indication of anxiolytic and/or hypnotic. https://www.sefh.es/alertas/alertas8.htm. Accessed 11 Dec 2023.

30.

ABIM Foundation. Choosing Wisely. http://www.choosingwisely.org/. Accessed 11 Dec 2023.

31.

Nicieza-García ML, Salgueiro-Vázquez ME, Jimeno-Demuth FJ, et al. Beers versus STOPP criteria in polyharmacy community-dwelling older patients. Farm Hosp. 2016;40(3):150–64. https://doi.org/10.7399/fh.2016.40.3.9706.CrossRefPubMed

32.

Guisado-Clavero M, Violán C, López-Jimenez T, et al. Medication patterns in older adults with multimorbidity: a cluster analysis of primary care patients. BMC Fam Pract. 2019;20(1):82. https://doi.org/10.1186/s12875-019-0969-9.CrossRefPubMedCentralPubMed

33.

López-Pelayo H, Coma A, Gual A, et al. Call for action: benzodiazepine prescription prevalence analysis shows off-label prescription in one in eleven citizens. Eur Addict Res. 2019;25:320–9. https://doi.org/10.1159/000502518.CrossRefPubMed

34.

de las Cuevas C, Sanz E, de las Fuente J. Benzodiazepines: more “behavioural” addiction than dependence. Psychopharmacology. 2003;167:297–303. https://doi.org/10.1007/s00213-002-1376-8.CrossRefPubMed

35.

Ministry of Health. Pharmaceutical Benefit in the National Health System, 2020–2021. Monographic report. Reports, Studies and Research. 2022. [In Spanish]. https://cpage.mpr.gob.es/producto/informe-monografico-prestacion-farmaceutica-en-el-sistema-nacional-de-salud/. Accessed 22 Dec 2022.

36.

Díaz-Gutiérrez MJ, Martínez-Cengotitabengoa M, Bermúdez-Ampudia C, et al. Overdosing of benzodiazepines/Z-drugs and falls in older adults: costs for the health system. Exp Gerontol. 2018;110:42–5. https://doi.org/10.1016/j.exger.2018.05.002.CrossRefPubMed

37.

Marquina-Márquez A, Olry-de Labry-Lima A, Bermúdez-Tamayo C, Ferrer López I, Marcos-Marcos I. Identifying barriers and enablers for benzodiazepine (de)prescription: a qualitative study with patients and healthcare professionals. An Sist Sanit Navar. 2022;45(2):e1005. https://doi.org/10.23938/ASSN.1005.CrossRefPubMedCentralPubMed

38.

Kristen T, Milushewa P, Tachkov K. Impact of polypharmacy, drug-related problems, and potentially inappropriate medications in geriatric patients and its implications for Bulgaria - narrative review and meta-analysis. Front Public Health. 2022;10:743138. https://doi.org/10.3389/fpubh.2022.743138.CrossRef

39.

Lukačišinová A, Fialová D, Peel NM, et al. The prevalence and prescribing patterns of benzodiazepines and Z-drugs in older nursing home residents in different European countries and Israel: retrospective results from the EU SHELTER study. BMC Geriatr. 2021;21:277. https://doi.org/10.1186/s12877-021-02213-x.CrossRefPubMedCentralPubMed

40.

Akpinar A, Yaman AR, Karakus K, et al. The frequent of benzodiazepine use in the Isparta province. Klinik Psikofarmakol Bülteni. 2016;26(2):169–74. https://doi.org/10.5455/bcp.20150707103818.CrossRef

41.

Asicioglu F, Esra Kucukibrahimoglu E, Ilingi U. Psychotropic drugs evaluated in the context of narcotic drugs according to the new Turkish criminal law. Klinik Psikofarmakol Bülteni. 2010;20(4):314–20. https://doi.org/10.1080/10177833.2010.11790678.CrossRef

42.

Egan MY, Wolfson C, Moride Y, et al. High daily doses of benzodiazepines among Quebec seniors: prevalence and correlates. BMC Geriatr. 2001;1:4. https://doi.org/10.1186/1471-2318-1-4.CrossRefPubMedCentralPubMed

43.

Cloos JM, Bocquet V, Rolland-Portal I, et al. Hypnotics and triazolobenzodiazepines – best predictors of high-dose benzodiazepine use: results from the Luxembourg National Health Insurance Registry. Psychother Psychosom. 2015;84:273–83. https://doi.org/10.1159/000434755.CrossRefPubMed

44.

Chena Y, Liuc C, Change C, et al. Perceptions, clinical characteristics, and other factors associated with prolonged and high daily dose of benzodiazepine use among patients with anxiety or depressive disorders. J Affect Disord. 2020;271:215–23. https://doi.org/10.1016/j.jad.2020.03.077.CrossRef

45.

Davies SJ, Rudoler D, de Oliveira C, et al. Comparative safety of chronic versus intermittent benzodiazepine prescribing in older adults: a population-based cohort study. J Psychopharmacol. 2022;36(4):460–9. https://doi.org/10.1177/02698811211069096.CrossRefPubMedCentralPubMed

46.

National Institute for Health and Care Excellence (NICE). Dementia: Assessment, Management and Support for People Living with Dementia and Their Carers NICE Guidance [NG97]. https://www.nice.org.uk/guidance/ng97. Accessed 11 Dec 2023.

47.

Reus VI, Fochtmann LJ, Eyler AE, et al. The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. Am J Psychiatry. 2016;173:543–6.CrossRefPubMed

48.

Keltner NL, Folks DG. The omnibus budget reconciliation act: impact on psychotropic drug use in long-term care facilities. Perspect Psychiatr Care. 1995;31:30–3.PubMed

49.

Tannenbaum C, Martin P, Tamblyn R, et al. Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: the EMPOWER cluster randomized trial. JAMA Intern Med. 2014;174:890–8.CrossRefPubMed

50.

Breen J, Jackson S, Gee P, et al. An effective approach to decrease antipsychotic and benzodiazepine use in nursing homes: the RedUSe project. Int Psychogeriatr/IPA. 2009;22:26–36.

51.

Brodaty H, Aerts L, Harrison F, et al. Antipsychotic deprescription for older adults in long-term care: the HALT study. J Am Med Dir Assoc. 2018;19:592-600.e7.CrossRefPubMed

52.

Bednarczyk E, Cook S, Brauer R, Garfield S. Stakeholders‘ views on the use of psychotropic medication in older people: a systematic review. Age Ageing. 2022;51:1–11. https://doi.org/10.1093/ageing/afac060.CrossRef

53.

Jyrkka J, Englund H, Korhonen MJ, Sulkava R, Hartikainen S. Patterns of drug use and factors associated with polypharmacy and excesive polypharmacy in elderly persons. Drugs Aging. 2009;26(12):1039–48. https://doi.org/10.2165/11319530-000000000-00000.CrossRefPubMed

54.

Nothelle SK, Sharma R, Oakes A, Jackson M, Segal JB. Factors associated with potentially inappropriate medication use in community-dwelling older adults in the United States: a systematic review. Int J Pharm Pract. 2019;27(5):408–23. https://doi.org/10.1111/ijpp.12541.CrossRefPubMedCentralPubMed

55.

Dealberto MJ, Seeman T, McAvay GJ, et al. Factors related to current and subsequent psychotropic drug use in an elderly cohort. J Clin Epidemiol. 1997;50(3):357–64. https://doi.org/10.1016/s0895-4356(96)00339-3.CrossRefPubMed

56.

Newman SC, Hassan AI. Antidepressant use in the elderly population in Canada: results from a national survey. J Gerontol A Biol Sci Med Sci. 1999;54:M527-530. https://doi.org/10.1093/gerona/54.10.m527.CrossRefPubMed

57.

Olfson M, King M, Schoenbaum M. Benzodiazepine use in the United States. JAMA Psychiat. 2015;72(2):136–42. https://doi.org/10.1001/jamapsychiatry.2014.1763.CrossRef

58.

Anderson K, Stowasser D, Freeman C, et al. Prescriber barriers and enablers to minimising potentially inappropriate medications in adults: a systematic review and thematic synthesis. BMJ Open. 2014;4(12):e006544. https://doi.org/10.1136/bmjopen-2014-006544.CrossRefPubMedCentralPubMed

59.

Rivasi G, Kenny RA, Ungar A, et al. Effects of benzodiazepines on orthostatic blood pressure in older people. Eur J Intern Med. 2020;72:73–8. https://doi.org/10.1016/j.ejim.2019.10.032.CrossRefPubMed

60.

Brignole M, Rivasi G. New insights in diagnostics and therapies in syncope: a novel approach to non-cardiac syncope. Heart. 2020;107(11):864–73. https://doi.org/10.1136/heartjnl-2020-318261.CrossRef

61.

Gill TM, Murphy TE, Gahbauer EA, et al. Association of injurious falls with disability outcomes and nursing home admissions in community-living older persons. Am J Epidemiol. 2013;178(3):418–25. https://doi.org/10.1093/aje/kws554.CrossRefPubMedCentralPubMed

62.

Seppala LJ, Wermelink AMAT, de Vries M, et al. Fall-risk-increasing drugs: a systematic review and meta-analysis: II. Psychotropics J Am Med Dir Assoc. 2018;19(4):371.e11-371.e17. https://doi.org/10.1016/j.jamda.2017.12.098.CrossRefPubMed

63.

Xing D, Ma XL, Ma JX, et al. Association between use of benzodiazepines and risk of fractures: a meta-analysis. Osteoporos Int. 2014;25(1):105–20. https://doi.org/10.1007/s00198-013-2446-y.CrossRefPubMed

64.

Cooper SJ. Benzodiazepines and appetite: recent pre-clinical advances and their clinical implications. Hum Psychopharmacol: Clin & Experiment. 1989;4(2):81–9. https://doi.org/10.1002/hup.470040203.CrossRef

65.

Ashton H. Benzodiazepines: How they work & how to withdraw. Revised August 2022. Newcastle University. https://benzo.org.uk/manual/. Accessed 22 Dec 2022.

Title: Prevalence, country-specific prescribing patterns and determinants of benzodiazepine use in community-residing older adults in 7 European countries
Authors: Anna Lukačišinová
Jindra Reissigová
Maja Ortner-Hadžiabdić
Jovana Brkic
Betul Okuyan
Daisy Volmer
Ivana Tadić
Pilar Modamio
Eduardo L. Mariño
Konstantine Tachkov
Rosa Liperotti
Graziano Onder
Harriet Finne-Soveri
Hein van Hout
Elizabeth P. Howard
Daniela Fialová
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: Benzodiazepine
Diazepam
Lorazepam
Published in: BMC Geriatrics / Issue 1/2024
Electronic ISSN: 1471-2318
DOI: https://doi.org/10.1186/s12877-024-04742-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2024

Development and validation of the osteoporosis scale among the system of quality of life instruments for chronic diseases QLICD-OS (V2.0)

A novel score for predicting falls in community-dwelling older people: a derivation and validation study

Combined effects of vitamin D deficiency and systemic inflammation on all-cause mortality and cause-specific mortality in older adults

Does the intensity of pain and disability affect health-related quality of life of older adults with back pain? Multilevel analysis between Brazil and Netherlands: a cross-sectional study of the BACE consortium

Status of age-friendly city indicators in Iran cities: a systematic review

Activities of daily living limitations and the use of physical examination among older adults with informal care in China: do gender and residence make differences?

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials